Mid-Atlantic BioTherapeutics, Inc. — Form D
Mid-Atlantic BioTherapeutics, Inc. of DOYLESTOWN, PA, a company, filed a Form D exempt-offering notice with the SEC on 2018-10-11. The offering totals $10.0M, of which $875K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2018-10-11
- Form: D
- Accession: 0001445866-18-001101
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $10.0M
- Amount sold: $875K
- Remaining: $9.1M
- Minimum investment: $25K
- Investors: 1
- Date of first sale: 2018-06-28
- Security types: equity
- Revenue range: No Revenues
- SEC file number: 021-323321
Issuer
- Name: Mid-Atlantic BioTherapeutics, Inc.
- CIK: 0001755678
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 3805 OLD EASTON ROAD, DOYLESTOWN, PA, 18902
- Phone: 215-266-2301
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Jean Pierre Gagnon | Executive Officer | Doylestown, PA |
| Andrew Katz | Director | Nashville, TN |
| Julian Chick | Director | Doylestown, PA |
| David Horn | Director | Doylestown, PA |
| David Horn | Executive Officer | Doylestown, PA |
| Michael Goldblatt | Director | Doylestown, PA |
| David Jobes | Director | Doylestown, PA |
| David Jobes | Executive Officer | Doylestown, PA |
| Jean Pierre Gagnon | Director | Doylestown, PA |
Other filings by this issuer (1)
More